Lutetium [177Lu] oxodotreotide/dotatate is named as an intervention in 2 current clinical trials in our Spain, UK, USA, France and Poland registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Advanced Accelerator Applications (1). The most-studied condition is Gastroenteropancreatic Neuroendocrine Tumors.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Spanish Series of Patients Treated With the Radionuclide Lutetium177
NCT04949282 · ClinicalTrials.gov ↗ · Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms
|
Observational | Recruiting | Sociedad Española de Medicina Nuclear e Imagen Molecular | Spain |
|
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
NCT04711135 · ClinicalTrials.gov ↗ · Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
|
Phase 2 | Active, closed | Advanced Accelerator Applications | UK, USA, France, Spain, Poland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Advanced Accelerator Applications | 1 |
| Sociedad Española de Medicina Nuclear e Imagen Molecular | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Spain | 2 | 1 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 0 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Poland | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Spain, UK, USA, France and Poland registers name Lutetium [177Lu] oxodotreotide/dotatate as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Spain. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Advanced Accelerator Applications (1) and Sociedad Española de Medicina Nuclear e Imagen Molecular (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lutetium [177Lu] oxodotreotide/dotatate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lutetium [177Lu] oxodotreotide/dotatate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lutetium [177Lu] oxodotreotide/dotatate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.